德琪医药-B聚焦肿瘤领域的创新先锋,TCE 2.0蓄势待发

太平洋证券
Jun 05, 2025

一、公司核心竞争力与投资逻辑德琪医药作为一家专注于肿瘤学和免疫学领域的创新药企业,其核心竞争力体现在多维度的研发管线布局和商业化能力。首先,塞利尼索作为公司首款商业化产品,已在多个亚太市场获批上市,并纳入医保目录,为公司提供了稳定的现金流支撑。随着适应症的扩增和上市地区的增加,塞利尼索销售收入有望持续增长。此外,公司在研管线中ATG-022(CLDN18.2ADC)和ATG-037(CD73小分子...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10